Biotechnology

Korro Bio

William Blair analyst downgrades Korro Bio to hold rating, Clear Street maintains buy rating

Korro Bio released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 1.09 M (forecast USD 411.56 K), actual EPS USD -1.9231 (forecast USD -2.5888)

Korro Bio released FY2025 9 Months Earnings on November 12, 2025 (EST) with actual revenue of USD 4.01 M and EPS of USD -5.2364

Rahimi gives Korro Bio Strong Buy Rating

Korro Bio released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 1.46 M (forecast USD 406.9 K), actual EPS USD -2.7442 (forecast USD -2.5644)

Korro Bio released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 4.01 M, actual EPS USD -5.2369

Korro Bio Showcases RNA Editing Technology for Rare Disease Treatment

Korro Bio Inc. Elects New Directors and Approves EY as Auditor

H.C. Wainwright Downgrades KORRO BIO Price Target

Korro Bio released FY2025 Q1 earnings on May 7 (EST), actual revenue USD 2.55 M (forecast USD 379 K), actual EPS USD -2.4921 (forecast USD -2.6133)

Korro Bio Inc Announces 20% Layoffs

Korro Bio Reports Q1 2025 Earnings and Announces Operational Simplification

Royal Bank of Canada Lowers Korro Bio Target Price to $95, Potential Upside of 293.78%

Korro Bio released FY2024 Q4 earnings on March 18 (EST), actual revenue 2.271 M USD (forecast 0 USD), actual EPS -2.2631 USD (forecast -2.48 USD)

Korro Bio released FY2024 annual earnings on March 18 (EST), actual revenue 2.271 M USD (forecast 0 USD), actual EPS -9.3694 USD (forecast -9.2585 USD)

Korro Bio, Inc. Reports Financial Status and Drug Development Progress for 2024

Korro Bio is set to release its earnings report on March 25, with analysts expecting a loss of $2.41 per share

Korro Bio Receives FDA Orphan Drug Designation for KRRO-110 to Treat Alpha-1 Antitrypsin Deficiency

Korro Bio released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of 0 and EPS of -7.1245

Korro Bio released FY2024 Q3 earnings on November 12 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -2.2571 USD (forecast -2.61 USD)

AMC Robotics

Radiopharm Theranostics

Artiva Biotherapeutics

Netclass Tech

3 E Network Tech

Quipt Home Medical

Kaixin

Ascent Solar Tech

Click Holdings/BVI

Climb Bio

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap